News | April 07, 2008

Bi-Atrial Lesion Pattern Produces Positive Positive Results in Afib Patients

April 8, 2008 - Atrial fibrillation demonstrated that a port access, paracardioscopic Ex-Maze procedure produced favorable outcomes and allowed patients to discontinue antiarrhythmic drugs, according to interim results from a study presented by Andy C. Kiser, M.D., at the American College of Cardiology meeting in Chicago, IL.

Epicardial lesions to complete the bi-atrial pattern were created in all patients by coagulating cardiac tissue using the nContact Surgical VisiTrax device.

The 37 patients reported in the study had an average age of 61 years, a mean duration of atrial fibrillation of 7.4 years, and a mean left atrial size of 5.7 cm. Seventy-eight percent of the patients had long-standing persistent atrial fibrillation. Analysis of three-month interim outcomes demonstrated normal sinus rhythm in 17/20 (85 percent) patients. For those patients who had reached six months, 7/7 (100 percent) patients experienced normal sinus rhythm without antiarrhythmic drugs.

"This is a truly minimally invasive approach that treats both the left and right atrium without the use of cardiopulmonary bypass,"? stated Dr. Kiser. "These interim closed-chest results are very promising, particularly, when intra-operative metrics, including spontaneous conversion to normal sinus rhythm and confirmed exit block, are met."

For more information: www.Ex-Maze.com and www.ncontactsurgical.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now